menu
    • menu

    Company profile for Ajanta Pharma Limited

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacture and marketing of quality finished dosages in domestic and international markets. Established in 1973 and headquartered in Mumbai-India, we are committed to 'Serve Health Care Needs Worldwide'. Ajanta has been consistently providing high quality affordable medicines to patients in different parts of the world. We employ over 4,000 people ...
    Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacture and marketing of quality finished dosages in domestic and international markets. Established in 1973 and headquartered in Mumbai-India, we are committed to 'Serve Health Care Needs Worldwide'. Ajanta has been consistently providing high quality affordable medicines to patients in different parts of the world. We employ over 4,000 people worldwide and our products are sold in over 40 countries. Ajanta operates with 5 state-of-the art manufacturing facilities that produce high quality pharmaceutical products. We focus on commercializing unique generic products and pioneering synergistic combination products in the therapeutic areas of anti-malarial, Cardiovascular, dermatology, male erectile dysfunction, musculoskeletal, and ophthalmology. In India, we have significant presence in the fast growing specialty therapeutic segments of Cardiovascular, dermatology, ophthalmology and musculoskeletal. With primary focus on new product innovation and introduction, we have been consistently identifying unmet medical needs and introducing many first-to-market products to cater to those needs. Our products provide patient compliance and convenience over existing therapeutic options. Gaining first mover advantage, many of our brands hold leadership positions in their respective sub- therapeutic segments. Ajanta has extensive presence in many countries in Asia, Africa and Latin America with customized product portfolio to suit the needs of each country. Having successfully gone through USFDA inspection, we have started commercial operations in the US market in the first quarter of 2013. With a portfolio of 23 ANDAs which have been filed with the US FDA, we look forward to the US market to be our key growth driver in coming years. We have an advanced Research & Development Centre for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms. ‘Advent’, our R&D centre has a team of over 300 scientists working on innovative products for various markets across the globe. We have acquired strong capabilities for developing generic formulations and process chemistry over the years. Committed to patient care since inception, our focus on specialty segments in India and simultaneous opening of new international markets has been accelerating our growth over the years. Ajanta’s team members are driven to fulfill its mission; a commitment to ‘Serving Global Healthcare needs with Empathy, Innovation & Technology’.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ajanta Pharma Limitedindia-flag Flag
    Country
    Country
    India
    Address
    Address
    98, Ajanta House, Charkop, Kandivili (West) Mumbai, 400 067, India
    Telephone
    Telephone
    91 22 6606 1000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.ajantapharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biocon Signs Out-Licensing Deal For Semaglutide With Ajanta
    Biocon Signs Out-Licensing Deal For Semaglutide With Ajanta

    23 Dec 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/biocon-inks-out-licensing-agreement-with-ajanta-to-market-semaglutide-in-26-countries-18659

    INDPHARMAPOST
    23 Dec 2025
    Share Share
    Ajanta’s Generics Dapagliflozin Receives Tentative Approval in US
    Ajanta’s Generics Dapagliflozin Receives Tentative Approval in US

    14 Oct 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211482

    FDA
    14 Oct 2025
    Share Share
    Ajanta`s Generics Topiramate Receives Approval in US
    Ajanta`s Generics Topiramate Receives Approval in US

    03 Sep 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219564

    FDA
    03 Sep 2025
    Share Share
    Ajanta Pharma Announces Q1 FY26 Consolidated PAT of Rs. 255.34 Cr
    Ajanta Pharma Announces Q1 FY26 Consolidated PAT of Rs. 255.34 Cr

    30 Jul 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/ajanta-pharma-reports-q1-fy26-consolidated-pat-at-rs-25534-cr-17501

    INDPHARMAPOST
    30 Jul 2025
    Share Share
    Ajanta Generics Sitagliptin Receives Tentative Approval in US
    Ajanta Generics Sitagliptin Receives Tentative Approval in US

    24 Jul 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216516

    FDA
    24 Jul 2025
    Share Share
    Ajanta Pharma Ltd spurts 2.5%, up for five straight sessions
    Ajanta Pharma Ltd spurts 2.5%, up for five straight sessions

    03 Feb 2025

    // BUSINESS STD

    https://www.business-standard.com/markets/capital-market-news/ajanta-pharma-ltd-spurts-2-5-up-for-five-straight-sessions-125020300500_1.html

    BUSINESS STD
    03 Feb 2025
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Duloxetine Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Duloxetine Hydrochloride

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2022-10-18

    Pay. Date : 2022-09-29

    DMF Number : 37458

    Submission : 2022-09-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Ranolazine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Ranolazine

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2023-07-12

    Pay. Date : 2023-06-21

    DMF Number : 37993

    Submission : 2023-02-06

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Valganciclovir Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Valganciclovir Hydrochloride

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2021-12-03

    Pay. Date : 2021-10-13

    DMF Number : 36194

    Submission : 2021-10-22

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Voriconazole

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Voriconazole

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2023-10-23

    Pay. Date : 2023-09-13

    DMF Number : 38332

    Submission : 2023-05-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Cefadroxil

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    Cefadroxil

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 14201

    Submission : 1999-06-14

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    MANUFACTURED SITE, FACILITIES, PERS...

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    MANUFACTURED SITE, FACILITIES, PERS...

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 12402

    Submission : 1997-03-05

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Meclofenamic Acid

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    08

    Pilocarpine Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow

    09

    Polmacoxib

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    BIO Partnering at JPM
    Not Confirmed
    arrow
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Biocon Signs Out-Licensing Deal for Semaglutide with Ajanta

    Details:

    Through the licensing deal for Semaglutide, a peptide targeting the GLP-1 receptor, the agreement aims to advance treatments for type-2 diabetes.


    Lead Product(s): Semaglutide

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Recipient: Biocon

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement December 23, 2025

    blank

    01

    Ajanta Pharma Limited

    India
    arrow
    Biotech Showcase
    Not Confirmed

    Ajanta Pharma Limited

    India
    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Semaglutide

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Recipient : Biocon

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Biocon Signs Out-Licensing Deal for Semaglutide with Ajanta

    Details : Through the licensing deal for Semaglutide, a peptide targeting the GLP-1 receptor, the agreement aims to advance treatments for type-2 diabetes.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Undisclosed

    December 23, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Ajanta Pharma Limited and get a quotation

    Ajanta Pharma Limited is a supplier offers 9 products (APIs, Excipients or Intermediates).

    Find a price of Duloxetine Hydrochloride bulk with DMF offered by Ajanta Pharma Limited

    Find a price of Ranolazine bulk with DMF offered by Ajanta Pharma Limited

    Find a price of Valganciclovir Hydrochloride bulk with DMF offered by Ajanta Pharma Limited

    Find a price of Voriconazole bulk with DMF offered by Ajanta Pharma Limited

    Find a price of Cefadroxil bulk offered by Ajanta Pharma Limited

    Find a price of MANUFACTURED SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN MAHARASHTRA, INDIA bulk offered by Ajanta Pharma Limited

    Find a price of Meclofenamic Acid bulk offered by Ajanta Pharma Limited

    Find a price of Pilocarpine Hydrochloride bulk offered by Ajanta Pharma Limited

    Find a price of Polmacoxib bulk offered by Ajanta Pharma Limited

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search